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ABSTRACT
Cyclooxygenase (COX)-2 inhibitors demonstrate modest antineoplastic
activity in experimental models of human malignancies, but little is known
about factors that may confer resistance to their antiproliferative actions.
We observed that fetal bovine serum antagonizes growth inhibition and
G1 arrest induced by two COX-2 inhibitors (NS-398 and celecoxib) on
BxPC-3 pancreatic cancer cells. We investigated the hypothesis that
insulin-like growth factor I (IGF-I), a major survival factor present in
serum, mediates these effects. Treatment of BxPC-3 cells with 25 M
celecoxib in 1% fetal bovine serum-containing medium for 48 h resulted
in a 40% decrease in cell viability. Coincubation of BxPC-3 cells with 25
M celecoxib and 50 ng/ml IGF-I resulted in complete attenuation of the
celecoxib-associated decrease in cell viability. Cell cycle analysis revealed
that this IGF-I-induced increase in cell viability was correlated with an
IGF-I-induced inhibition of celecoxib-mediated G1 arrest. Similar results
were observed when another COX-2 inhibitor (50 M NS-398) was used.
When IGF-binding protein-3 (an inhibitor of IGF-I bioactivity) was added
in combination with 25 M celecoxib, enhanced growth inhibition was
observed (60% decrease in cell viability). Treatment of BxPC-3 cells
with a higher dose (50 M) of celecoxib for 24 h resulted in the induction
of apoptosis, as assayed by flow cytometry and poly(ADP-ribose) poly-
merase cleavage. Addition of 50 ng/ml IGF-I resulted in a complete
attenuation of celecoxib-induced apoptosis. The protection from celecoxib-
induced apoptosis by IGF-I correlated with an increase in the levels of the
activated antiapoptotic protein Akt. These results suggest that alterations
of IGF-I levels or IGF-I receptor signal transduction modulate the anti-
neoplastic actions of COX-2 inhibitors.
INTRODUCTION
A large body of data has suggested a role for NSAIDs
2 in the
treatment or prevention of various cancers. The classic actions of
NSAIDs involve inhibition of the rate-limiting enzyme in the pros-
taglandin synthesis cascade, COX. This enzyme exists in two iso-
forms: COX-1 and COX-2. The expression of COX-1 is constitutive
in most tissues, whereas the expression of COX-2 is inducible by
cytokines, growth factors, and tumor promoters (1).
Several reports show that many types of malignant tissues overex-
press the COX-2 enzyme (2, 3), and that NSAIDs inhibit proliferation
and/or induce apoptosis in various cancer cell lines both in vitro (4, 5)
and in vivo (6, 7). It is believed that these antineoplastic effects are
because of inhibition of prostaglandin synthesis and modification of
other non-COX targets (reviewed in Ref. 8). Administration of
COX-2 selective NSAIDs (COX-2 inhibitors) to patients minimizes
the gastrointestinal tract toxicity associated with COX-1 inhibition
(9), and it is hopeful that COX-2 inhibitors can be used in the clinic
in combination with other agents for the treatment of various cancers.
Although the antineoplastic actions of COX-2 inhibitors have been
well documented in the literature, little is known about factors that
may confer resistance to their effect. Chang and Weng (10) have
proposed that the cytotoxic effect of COX-2 inhibitors on cancer cells
may be influenced by the extracellular environment. This hypothesis
was based on their results showing that NS-398 induced apoptosis in
A549 lung cancer cells under serum-free conditions, whereas this drug
induced G1 arrest rather than apoptosis in cells treated in 10% serum
medium.
We wished to additionally clarify whether serum has an effect on
the antineoplastic activity of COX-2 inhibitors. We chose to investi-
gate this hypothesis in a pancreatic cancer cell line, because treatment
of pancreatic cancer represents an unmet medical need. Furthermore,
COX-2 inhibitors have been shown to inhibit the growth of several
pancreatic cancer cell lines in vitro (11, 12), and COX-2 levels are
elevated in human pancreatic adenocarcinomas when compared with
the surrounding stroma (13). As well, COX-2 inhibitors have been
shown to enhance the cytotoxic effect of gemcitabine on pancreatic
cancer cells in vitro (14).
We demonstrate that IGF-I, a component of serum, inhibits the
antiproliferative effects of two COX-2 inhibitors (NS-398 and cele-
coxib) on BxPC-3 pancreatic cancer cells. Conversely, we show that
IGFBP-3, a protein that inhibits IGF-I receptor activation by seques-
tering IGF-I (15), enhances celecoxib-induced growth inhibition. Fur-
thermore, we show that IGF-I protects BxPC-3 cells from celecoxib-
induced apoptosis. IGF-I is known to activate the antiapoptotic protein
Akt (16), and because down-regulation of Akt activity has been
hypothesized as one of the mechanisms involved in celecoxib-induced
apoptosis (4), we also show that IGF-I and celecoxib have opposing
effects on Akt activation in our experimental system.
MATERIALS AND METHODS
Cell Line and Treatment. BxPC-3 pancreatic cancer cells (American
Type Culture Collection, Manassas, VA) were cultured in RPMI 1640 sup-
plemented with 10% FBS at 37°C and 5% CO2. These cells have been shown
previously to express high levels of COX-2 protein and are growth inhibited by
NSAIDs (11, 12).
Celecoxib was obtained from Searle Pharmacia (St. Louis, MO). A stock
solution of 50 mM in DMSO was used. NS-398 was purchased from Cayman
Chemical (Ann Arbor, MI). A stock solution of 100 mM in DMSO was used.
Stock solutions were added to the test medium at dilutions of at least 1:1000,
and control samples were treated with vehicle (DMSO). The concentration of
DMSO in the test medium never exceeded 0.1% (v/v). IGF-I and recombinant
human IGFBP-3 were obtained from Protigen Incorporation (Mountain View,
CA) and were added to test medium to a final concentration of 50 ng/ml and
1 g/ml, respectively.
Cell Proliferation Assay. We used a MTT assay to determine cell prolif-
eration (cell viability). Cells (3  10
5) were plated in six-well plates in
medium containing 10% FBS. After 24 h, the cells were 40% confluent, and
the medium was changed to test medium specific for each experiment. After
48 h, MTT (Sigma Chemical Co., St. Louis, MO) was added to a final
concentration of 1 mg/ml, and the reaction mixture was incubated for3ha t
37°C. The resulting crystals were dissolved in 0.04% HCl in isopropanol, and
the absorbance was read at 562 nm.
Flow Cytometry to Assay Cell Cycle Distribution and Apoptosis. Cells
were plated in medium containing 10% FBS, and after 24 h, the cells were
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experiment. After 24 h, adherent cells were collected using trypsin-EDTA, and
floating cells were collected by centrifugation. The cells were combined and
washed twice with ice-cold PBS, and fixed in 70% ethanol at 20°C over-
night. For cell cycle analysis, the cells were washed twice with ice-cold PBS
and resuspended in propidium iodide buffer (PBS, 0.1% Triton X-100, 0.1 mM
EDTA, 0.05 mg/ml RNase A, and 50 M propidium iodide). After 30 min at
room temperature, the cell cycle distribution was determined by flow cytom-
etry with a FACScan (Beckman Coulter, Fullerton, CA). The proportion of
cells in the hypodiploid (sub-G1) area were considered to be apoptotic.
Western Blotting. After each treatment, both floating and adherent cells
were lysed in radioimmunoprecipitation assay buffer (0.1 mM dibasic sodium
phosphate, 1.7 mM monobasic phosphate, 150 mM NaCl, 1% NP40, 0.5% SDS,
0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride, and aprotinin
at 0.2 units/ml). Protein from clarified lysates (40 g) was resolved electro-
phoretically on denaturing 10% SDS-polyacrylamide gel and transferred to a
nitrocellulose membrane. Membranes were probed with antibodies specific for
cleaved PARP (Biosource, Camarillo, CA), COX-2 (Cayman Chemical, Ann
Arbor, MI), phospho-
473Ser-Akt (New England Biolabs, Beverly, MA), or
total Akt (New England Biolabs). The position of protein was visualized with
horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA). To confirm equal loading, membrane was stripped
and reprobed using an antibody specific for -tubulin (Santa Cruz Biotech-
nology, Santa Cruz, CA).
Statistical Analysis. All of the data are shown as means  SE. To assess
the statistical significance of observed differences, we used Student’s t test. All
of the tests were two-sided, and Ps  0.05 were considered to be statistically
significant.
RESULTS AND DISCUSSION
To determine whether modulation of FBS concentration in culture
medium influences the antiproliferative actions of COX-2 inhibitors
on pancreatic cancer cells, we treated BxPC-3 cells for 48 h with 50
M NS-398, 25 M celecoxib, or 50 M celecoxib in medium con-
taining either a low (1%) or high (10%) FBS concentration. As seen
in Fig. 1A, increasing the FBS concentration in the culture medium
significantly diminished the efficacy of the COX-2 inhibitors to
inhibit BxPC-3 proliferation. This effect was most dramatic for the 50
M celecoxib treatment condition, where treatment under 1% FBS
conditions resulted in virtually no viable cells after 48 h, whereas
treatment under 10% FBS conditions resulted in 50% of the cells
remaining viable. Fig. 1B illustrates that the protective effect of FBS
against 50 M celecoxib-induced growth inhibition is consistent over
many FBS concentrations.
To additionally investigate this observation, cell cycle analysis was
performed after 24-h treatment. As seen in Fig. 2A, treatment with 50
M NS-398 or 25 M celecoxib in 1% FBS-containing medium results
in the induction of G1 arrest (18% increase in the proportion of cells
in G1 for 50 M NS-398 and 14% increase for 25 M celecoxib).
Repeating these treatment conditions in 10% FBS-containing medium
(Fig. 2B) results in a decrease in the induction of G1 arrest (9%
increase in the proportion of cells in G1 for 50 M NS-398, and 5%
increase for 25 M celecoxib). These results are consistent with those
of Yip-Schneider et al. (14), who have shown that NSAIDs induce G1
arrest in BxPC-3 cells by decreasing the expression of various cyclins
and increasing the expression of the cyclin-dependent kinase inhibi-
tors p21 and p27.
Under 1% FBS conditions, treatment with 50 M celecoxib resulted
in a 40% increase in the proportion of cells undergoing apoptosis, with
no induction of G1 arrest (Fig. 2A). In the presence of 10% FBS, the
apoptosis induction by 50 M celecoxib was completely blocked (Fig.
2B), although G1 arrest was observed (25% increase in the proportion
of cells in G1). The switch from apoptosis to G1 arrest as a function
of serum concentration was correlated with an attenuation of the
growth inhibitory actions of 50 M celecoxib, as demonstrated by the
cell viability data in Fig. 1.
There are two possible explanations for the observed effects of
FBS. One hypothesis is that growth factors present in FBS could
increase COX-2 expression, overcoming the NSAID-induced inhibi-
tion of COX-2 activity. This hypothesis was disproved by Western
blotting showing that COX-2 protein levels remained constant when
the FBS concentration in the culture medium was varied between 1%
and 10% (data not shown). An alternate hypothesis is that components
of FBS are inducing survival signals in BxPC-3 cells, protecting them
from the effects of the COX-2 inhibitors. One candidate molecule
present in FBS is IGF-I. Activation of the IGF-I receptor by IGF-I
results in the induction of the phosphatidylinositol 3-kinase/Akt and
mitogen-activated protein kinase pathways, which are known to pro-
mote mitogenesis and survival in a variety of cell types (reviewed in
Ref. 16).
To determine whether IGF-I could be mediating the observed
effects of FBS in this system, BxPC-3 cells were treated with COX-2
inhibitors in 1% FBS, with or without exogenous IGF-I (50 ng/ml). It
should be noted that no significant changes in COX-2 protein expres-
sion were detected on IGF-I addition in this system (data not shown).
As seen in Fig. 3A, treatment with 50 M NS-398 or 25 M celecoxib
for 48 h resulted in a 40% decrease in cell viability. Coincubation
with the NSAID and IGF-I resulted in a complete attenuation of the
NSAID-associated decrease in cell viability. This effect was accom-
panied by a complete blocking of the NSAID-induced G1 arrest
(Fig. 3B).
Fig. 1. FBS antagonizes NSAID-induced growth inhibition. BxPC-3 cells were treated
for 48 h in the presence of either 50 M NS-398, 25 M celecoxib (Cx), or 50 M Cx using
various FBS concentrations. Cell viability was determined by the MTT assay, and the
results are expressed as a percentage of the control sample with identical FBS concen-
tration. All changes in cell viability because of increasing the FBS concentration were
statistically significant with P  0.05; bars, SD.
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induced growth inhibition, we wished to determine whether an inhib-
itor of IGF-I would be able to enhance the antiproliferative actions of
COX-2 inhibitors. To study this hypothesis, we chose to use IGFBP-3,
a known inhibitor of IGF-I bioactivity, which acts by sequestering
IGF-I and preventing its activation of the IGF-I receptor (15). Fig. 3C
(Lane 4) shows that 1 g/ml IGFBP-3 alone has a modest growth-
inhibitory effect on BxPC-3 cells growing in 1% FBS-containing
medium (20% decrease in cell viability). When 1 g/ml IGFBP-3
was added in combination with 25 M celecoxib, additive growth
inhibition was observed with the combination treatment resulting in a
60% decrease in cell viability (Fig. 3C, Lane 5). As expected, when
1 g/ml IGFBP-3 was added to cells treated with both IGF-I and
celecoxib, the protective effect of IGF-I was completely abolished
(Fig. 3C, Lane 6), as the growth inhibition was similar to that
observed for celecoxib alone (40% decrease in cell viability).
As seen in Fig. 3A, IGF-I has no effect on cells treated with 50 M
celecoxib in 1% FBS-containing medium. However, when the back-
ground FBS concentration was increased to 5% FBS (Fig. 4A), addi-
tion of 50 ng/ml IGF-I resulted in a 16% increase in cell viability. This
observation raises the possibility that IGF-I is working in synergy
with another growth factor in FBS to confer resistance to the antipro-
liferative actions of 50 M celecoxib. Treatment with 50 M celecoxib
in 5% FBS-containing medium results in a 16% increase in the
proportion of apoptotic cells compared with control (Fig. 4B, panel 2).
Coincubation of 50 ng/ml IGF-I with 50 M celecoxib resulted in a
complete block of apoptosis induction (Fig. 4B, panel 3). However, in
the presence of IGF-I, 50 M celecoxib did induce a substantial G1
arrest (17% increase in the proportion of cells in G1 compared with
control). This result parallels our prior observation that increasing the
FBS concentration from 1% to 10% attenuates 50 M celecoxib-
induced growth inhibition by promoting a switch from apoptosis to G1
arrest (Fig. 2).
To verify the antiapoptotic effect of IGF-I, a second apoptosis end
point was used, namely PARP cleavage. As seen in Fig. 4C, treatment
with 50 M celecoxib in 5% FBS-containing medium for 24 h resulted
in an increase in the amount of cleaved PARP (Fig. 4C, Lane 2)
indicating the induction of apoptosis. PARP cleavage was completely
blocked by the addition of IGF-I (Fig. 4C, Lane 4). The lack of
apoptosis induction by 50 M celecoxib in 10% FBS containing
Fig. 2. FBS protects BxPC-3 cells from undergoing NSAID-induced G1 arrest and
apoptosis. BxPC-3 cells were treated with the indicated concentrations of either NS-398
or celecoxib (Cx) for 24 h in either 1% FBS (A) or 10% FBS (B). Cell cycle analysis was
determined using propidium iodide staining and flow cytometry. Data are presented as
percentage of cells in a particular stage of the cell cycle with the cells in the hypodiploid
(sub-G1) area representing apoptotic cells.
Fig. 3. IGF-I antagonizes NSAID-induced growth inhibition. A, BxPC-3 cells were
treated for 48 h with the indicated NSAIDs with or without the addition of 50 ng/ml IGF-I.
Cell viability was determined by the MTT assay, and the results are expressed as a
percentage of the control sample. Statistically significant changes in cell viability
(P  0.05) are marked with . B, BxPC-3 cells treated for 24 h were subjected to cell cycle
analysis by propidium iodide staining and flow cytometry. Data shown are the percentage
of cells in the G1 phase under each condition. C, BxPC-3 cells were treated for 48 h with
25 M celecoxib, with or without the addition of 50 ng/ml IGF-I and/or 1 g/ml IGFBP-3.
Cell viability was determined by the MTT assay, and the results are expressed as a
percentage of the control sample; bars, SD.
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end point. As expected, no induction of apoptosis was observed (Fig. 4C,
Lane 6).
The fact that IGF-I protected BxPC-3 cells from 50 M celecoxib-
induced apoptosis is consistent with other publications that demon-
strate the protective actions of IGF-I against apoptosis induced by
other means (17, 18). We next wished to investigate the downstream
effectors of IGF-I signaling that lead to protection from apoptosis in
our system. As down-regulation of Akt activity has been hypothesized
as one of the mechanisms involved in celecoxib-induced apoptosis
(4), one strong candidate was the IGF-I receptor/phosphatidylinositol
3-kinase/Akt pathway, which leads to phosphorylation and activation
of the serine/threonine kinase Akt (16). P-Akt subsequently phos-
phorylates and inactives several proapoptotic proteins such as
pro-caspase-9 and Bad (19).
As seen in Fig. 5, treatment of BxPC-3 cells with 50 M celecoxib
for 4 h reduced the low level of P-Akt present under control condi-
tions (Fig. 5, Lane 2 versus Lane 1). As expected, IGF-I (50 ng/ml)
significantly up-regulated P-Akt levels (Fig. 5, Lane 3). Importantly,
coincubation with celecoxib and IGF-I revealed titratable effects of
their opposing effects on P-Akt levels (Fig. 5, Lane 4). The IGF-I-
induced increase in P-Akt could at least partially explain the anti-
apoptotic effect of IGF-I in this system. These results are consistent
with those of Hsu et al. (4), who have shown that overexpression of
constitutively active Akt in PC-3 prostate cancer cells protected
against celecoxib-induced apoptosis.
At the 24-h time point, the observed decrease in P-Akt by celecoxib
(Fig. 5, Lane 6) and increase in P-Akt by IGF-I (Fig. 5, Lane 7) are
similar to those observed at 4 h. However, when IGF-I and celecoxib
were added in combination for 24 h (Fig. 5, Lane 8), we observed
virtually no P-Akt present. Therefore, the titration of P-Akt levels by
IGF-I and celecoxib is time dependent, with IGF-I having an earlier
effect than celecoxib. These results are consistent with the possibility
of the activation of a celecoxib-induced phosphatase that acts on Akt.
In this report, we show that the peptide hormone IGF-I interferes
with the ability of COX-2 inhibitors to promote G1 arrest and induce
apoptosis in pancreatic cancer cells. These results suggest that growth
factors present in serum, such as IGF-I, can influence the antiprolif-
erative actions of COX-2 inhibitors and attenuate their activity. Such
studies may lead to therapeutic strategies to optimize the use of
COX-2 inhibitors in the treatment of pancreatic cancer.
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